Table of Contents:
1 Report Prologue
2 Introduction
2.1 DEFINITION
2.2 SCOPE OF STUDY:
2.2.1 RESEARCH OBJECTIVE
2.3 ASSUMPTIONS & LIMITATIONS
2.3.1 ASSUMPTIONS
2.3.2 LIMITATIONS
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising R&D Funding for HIV Vaccine
4.2.2 Rising prevalence of HIV due to Prostitution
4.2.3 Increasing awareness due to HIV prevention programs
4.2.4 Growing number of new entrants in the market
4.3 Restraints
4.3.1 HIV vaccine Approvals
4.4 Challenges
4.4.1 Lack of natural immunity to HIV
4.4.2 Variability of HIV types
4.4.3 Animal model trials
5 Market Factor Analysis
5.1 Investment Opportunity Analysis
6 Global HIV Vaccine Market, By clinical Trials
6.1 Introduction
6.1.1 Phase I
6.1.2 Phase II
6.1.3 Phase III
7 Global HIV Vaccine Market, By Region
7.1 Introduction
7.2 North America
7.3 Europe
7.4 Asia Pacific
8 Competitive Landscape
8.1 Introduction
8.1.1 Collaboration
8.1.2 Acquisition
8.1.3 Agreement
8.1.4 Partnership
9 COMPANY PROFILE
9.1 Argos Therapeutics, Inc.
9.1.1 Company Overview
9.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.1.3 Financials
9.1.4 Key Developments
9.2 Bionor Pharma ASA
9.2.1 Company Overview
9.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.2.3 Financials
9.2.4 Key Developments
9.3 Janssen Global Services, LLC
9.3.1 Company Overview
9.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.3.3 Financials
9.3.4 Key Developments
9.4 GENECURE LLC
9.4.1 Company Overview
9.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.4.3 Financials
9.4.4 Key Developments
9.5 GeoVax
9.5.1 Company Overview
9.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.5.3 Financials
9.5.4 Key Developments
9.6 GENVEC, INC.
9.6.1 Company Overview
9.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.6.3 Financials
9.6.4 Key Developments
9.7 PaxVax Corporation
9.7.1 Company Overview
9.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.7.3 Financials
9.7.4 Key Developments
9.8 Inovio Pharmaceuticals, Inc.
9.8.1 Company Overview
9.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.8.3 Financials
9.8.4 Key Developments
9.9 GlaxoSmithKline plc
9.9.1 Overview
9.9.2 Product overview
9.9.3 Financials
9.9.4 Key Developments
9.1 SANOFI
9.10.1 COMPANY OVERVIEW
9.10.2 PRODUCT OVERVIEW
9.10.3 FINANCIALS
9.10.4 Key Developments
10 APPENDIX
10.1 DISCUSSION BLUE PRINT